Beiyun Zhou, PhD

Associate Professor of Medicine

Image of Beiyun Zhou, PhD
Is this your profile? Click to edit

Overview

Dr. Zhou’s research focuses on the delineation of mechanisms regulating alveolar epithelial cell (AEC) function, differentiation and plasticity in the context of lung injury and repair. A major focus has been to elucidate pathways (e.g., Hippo/YAP, Wnt/B-catenin, TGF-B/Smad, Forkhead box (Fox) and GATA6) as well as transcriptomic and epigenomic regulations that control differentiation of the alveolar epithelium (including pulmonary stem/progenitor cell proliferation/differentiation) in order to understand how they are altered in disease and injury. Her current studies engaged in to investigate the role of endoplasmic reticulum (ER) stress and the ER master regulator GRP78 in AEC abnormalities in chronic lung diseases such as idiopathic pulmonary fibrosis (IPF) using AEC-specific Grp78 knockout mice model. Her goal is to examine signaling pathways that modulate aberrant epithelial-mesenchymal interactions underlying ER stress-mediated fibrosis and identify new therapeutic approaches for pulmonary fibrosis.

Education and Training

  • University of Southern California, Los Angeles — Ph.D — 05/2018 — Molecular Pharmacology and Toxicology
  • Institute of Plant Physiology and Ecology,Chinese Academy of Sciences , Shanghai — M.S — 07/1988 — Microbiology

Research Funding

  • Role of Chaperone GRP78 and Mitochondrial Dysfunction in ER Stress-Mediated Pulmonary Fibrosis
    NIH · R01HL114959 · Aug 1, 2013 – Dec 31, 2025 · Role: Principal Investigator

Publications

  • AKT Signaling Differentially Regulates the Expression of Two Evolutionarily Conserved Wnt5a Isoforms in Lung Mesenchymal Cells. Cells. 2026 May 04; 15(9).. View in PubMed
  • Immortalization of Human Adult Alveolar Epithelial Cells to Study Environmental Exposures of the Distal Lung. Curr Protoc. 2026 May; 6(5):e70372.. View in PubMed
  • Non-invasive respiratory support attenuates lung damage in a murine model of bronchopulmonary dysplasia. Front Pediatr. 2026; 14:1755113.. View in PubMed
  • Nipocalimab and certolizumab combination therapy in participants with active rheumatoid arthritis despite prior treatment with advanced therapies: results from the phase 2a DAISY-RA study. RMD Open. 2026 Mar 04; 12(1).. View in PubMed
  • Targeting fibroblast-endothelial cell interactions in LAM pathogenesis using 3D spheroid models and spatial transcriptomics. JCI Insight. 2025 02 04; 10(6).. View in PubMed
  • Integrated multiomic analysis identifies TRIP13 as a mediator of alveolar epithelial type II cell dysfunction in idiopathic pulmonary fibrosis. Biochim Biophys Acta Mol Basis Dis. 2025 03; 1871(3):167572.. View in PubMed
  • Targeting Fibroblast-Endothelial Interactions in LAM Pathogenesis: 3D Spheroid and Spatial Transcriptomic Insights for Therapeutic Innovation. bioRxiv. 2024 Sep 06.. View in PubMed
  • Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study. RMD Open. 2024 06 28; 10(2).. View in PubMed
  • Alveolar type I cells can give rise to KRAS-induced lung adenocarcinoma. Cell Rep. 2023 12 26; 42(12):113286.. View in PubMed
  • Wnt5a Promotes AT1 and Represses AT2 Lineage-Specific Gene Expression in a Cell-Context-Dependent Manner. Stem Cells. 2022 07 27; 40(7):691-703.. View in PubMed